# Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients

> **NCT03781479** · PHASE2 · COMPLETED · sponsor: **Catalyst Pharmaceuticals, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Muscular Atrophy, Spinal

## Interventions

- **DRUG:** Amifampridine Phosphate
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03781479
- **Lead sponsor:** Catalyst Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-21
- **Primary completion:** 2020-07-23
- **Final completion:** 2020-07-23
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2021-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03781479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03781479, "Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03781479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*